H ypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease characterized by a hypertrophied, nondilated left ventricle (LV) in the absence of other causes. HCM is relatively common and is one of the most common causes of sudden death in athletes. 1 HCM is genotypically and phenotypically heterogenous. 2, 3 The differential diagnosis for HCM includes physiological remodeling seen in athlete's heart. 4 Distinguishing HCM from athlete's heart is of critical importance. Characteristics favoring HCM and athlete's heart are listed in the Table. An 18-year-old man was referred for evaluation after a markedly abnormal ECG ( Figure 1A ) was discovered at a professional hockey scouting event. He was otherwise healthy and asymptomatic. He had no family history of cardiomyopathies or sudden unexplained death. A contrast enhanced transthoracic echocardiogram showed apical HCM with a maximal LV wall thickness of 24 mm and spade-like appearance (Movie I in the Data Supplement). LV chamber size and systolic function were normal without dynamic obstruction. Diastolic function assessment showed indeterminate diastolic function grade. On cardiac MRI, the apex and anterior septum measured 25 and 13 mm, respectively (Figure 2A ; Movie II in the Data Supplement). First pass perfusion was normal, but postcontrast images demonstrated patchy areas of late gadolinium enhancement suggestive of fibrosis ( Figure 3A) . Exercise ECG and 24-hour Holter monitor showed no ventricular arrhythmias. On genetic testing, a de novo HCMassociated mutation in MYH7-encoded β myosin heavy chain gene at position 530 (p. Ile530Val) was identified. The patient's parents and 2 siblings, all phenotype negative for HCM, tested negative for the mutation.
The patient was counseled on the natural history of HCM and the risk of sudden death with competitive athletics. None of the standard sudden death risk markers were present at the initial evaluation, and therefore there was no indication for an implantable cardioverter defibrillator. The patient discontinued his rigorous athletic training, but continued to lead a relatively active lifestyle.
He was seen for follow-up 14 months after the initial diagnosis. Repeat cardiac MRI showed complete resolution of the LV hypertrophy with maximal wall thickness of 10 mm at the apex ( Figure 2B ; Movie III in the Data Supplement). However, the patchy areas of late gadolinium enhancement were unchanged ( Figure 3B ). On repeat noncontrast echocardiogram, maximum thickness was 12 mm at the apex (Movie IV in the Data Supplement). The ST depression and deeply inverted T waves were less prominent on his repeat ECG ( Figure 1B) . Because of the regression of hypertrophy after detraining and negative genetic testing in family members, genetic testing was repeated to exclude the possibility of a false-positive result, but he was again found to be genotype positive.
He continued to be asymptomatic until 16 months after the diagnosis when he developed presyncope and tachy-palpitations. An event recorder demonstrated episodes of supraventricular tachycardia and nonsustained ventricular tachycardia. Given his symptoms, documented nonsustained ventricular tachycardia, and late gadolinium enhancement on cardiac MRI, an implantable cardioverter defibrillator was implanted. Since the implantable cardioverter defibrillator placement, now >5 years ago, the patient has done well with no appropriate implantable cardioverter defibrillator discharges. On his most recent echocardiogram (6 years and 2 months since diagnosis), maximum thickness remained 12 mm at the apex.
These images demonstrate a novel case of LV hypertrophy regression after detraining in a patient with clinical HCM and an HCM-associated mutation. There are limited data supporting regression of LV hypertrophy with pharmacotherapy and surgical relief of outflow tract obstruction, but to our knowledge none on regression after detraining. At initial diagnosis, the extreme ECG changes, marked asymmetrical hypertrophy, late gadolinium enhancement, and genetic mutation were all consistent with an underlying pathological process (ie, sarcomeric HCM) rather than physiological adaptation. However, it is possible the patient has both athletic adaptation to intense training which has currently regressed and HCM.
Alternatively, this case may challenge the existing dogma that regression is only seen in physiological remodeling such as athlete's heart and that HCM phenotypic conversion is not altered by exogenous loads on the heart. Overall, it is of clinical importance to distinguish HCM and athlete's heart because of the differing recommendations and prognosis. The potential lifestyle restrictions for HCM have not only physical ramifications but also psychological and financial, as in this patient who was a professional athlete prospect.
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